Glutamate which is the main neurotransmitter in the brain is at the center of several different neurological and psychiatric diseases. Therefore, glutamate receptors (GluRs) are key therapeutic targets in the treatment of conditions associated with altered glutamatergic signaling and conditions which can be affected by alteration of glutamate level or signaling. Among these receptors, it has been shown that the positive modulation the metabotropic glutamate receptors (mGluRs) of group III (mGluR4, 6, 7 and 8) results in neuroprotection and pro-motor effects that can be beneficial in the treatment of several neurological disorders including Parkinson disease, Alzheimer’s disease, schizophrenia or autism. This poster will disclose in vitro and in vivo data of brain-penetrant compound, a potent pan-mGluR group III positive allosteric modulator. In particular, this compound shows anti-cataleptic effects in mice, at surprisingly low per os doses.

Discovery of a pan-mGluR PAM for the treatment of CNS disorders

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.